Symbol: ECTE

Current Price: $2.00

Snapshot – “ECTE is our new big biotech play for this week! Biotechs have just started to become very hot in 2010! ECTE is a transdermal medical device company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System as a platform technology for transdermal drug delivery. ECTE’s technology is revolutionary and the company believes that the Symphony tCGM System will change the paradigm of invasive, needle-based, pisodic glucose testing in the diabetes consumer and hospital critical care markets to one of continuous, needle-free monitoring. ECTE believes that the Symphony system is an ideal solution for diabetics and critically ill patients allowing for continuous, pain-free monitoring of glucose levels. The most common type of Diabeties, Type II, occurs in appx. 3 – 5% of Americans under 50 and 10 – 15% in those over 50. ECTE has uptrended since mid-December and we could see ECTE continue to uptrend!”

It is important to identify stocks in an uptrend, either at the start of an uptrend or in a sustained uptrend! ECTE is now in a type of sustained uptrend where it is also reaching new 52-week highs as well!

ECTE just reached a new 52-week high and we believe we could see ECTE keep uptrending and keep reaching new 52-week highs!

ECTE shattered resistance at $1.99, which we believe is now acting as a support level as well! We believe that the timing could not be better on ECTE!

ECTE released important news on January 11th that the company completed product development work on its Prelude™ SkinPrep System.

ECTE has signed a $15 million agreement, giving Ferndale Pharmaceuticals a license to develop, market and sell Prelude for enhanced delivery of Ferndale’s topical lidocaine product, LMX4, in North America and the UK. Echo received $750,000 up front and will receive $750,000 upon FDA approval, as well as $12.5 million in milestones and guaranteed minimum royalty payments. Echo will also receive a double digit royalty on net sales of the product.

The final Prelude device replaces the prototype device used in earlier clinical trials and will be tested in the near-term in a study using LMX4 lidocaine cream which should form the basis for a 510-k filing with Ferndale Pharma Group for the enhanced delivery of lidocaine. The Company believes that the addressable market for enhanced, fast acting topical lidocaine exceeds $1 billion.

We believe ECTE is a highly compelling stock that could create gains for investors over the next several trading days! ECTE has one-of-a-kind technology!

We will have more on this hot opportunity in the Biotech space! Keep up to date on ECTE within our Stock Hub and this Stock Newsletter!

Take the time to check out ECTE’s Web site at www.echotx.com for more information!